Julphar recently announced its 2030 growth strategy
Julphar will expand its presence into new territories, including CIS countries, Turkey, Latin America and Africa, to create new revenue streams
The pharma company announced it had seen top line growth and a return to a profitable bottom line compared to the previous year
The acquisition comes as part of efforts to boost Yas Holding’s healthcare manufacturing and distribution ecosystem
Julphar has inked a deal with G42 Medications Trading
The company has announced a net loss of Dhs25.6m for Q2 2020
The new capital is also expected to help it expand operations in key markets in the region
The kingdom banned Julphar’s products in September 2018 for failing to meet regional standards
Under the deal, EMD Millipore will sell recombinant human insulin manufactured by UAE-based pharmaceutical firm Julphar.
The pharmaceutical company has seen a profit rise of 5.6 per cent for the first half of last year, with operating profit also up.